Last reviewed · How we verify
GSK3640254 Mesylate Salt Capsule
At a glance
| Generic name | GSK3640254 Mesylate Salt Capsule |
|---|---|
| Sponsor | ViiV Healthcare |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants (PHASE1)
- A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults (PHASE2)
- A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants (PHASE1)
- A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK3640254 Mesylate Salt Capsule CI brief — competitive landscape report
- GSK3640254 Mesylate Salt Capsule updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI